Sage Therapeutics stockholders elect directors, ratify auditor, approve ESPP share increase

Sage Therapeutics, Inc.

Elected James Frates and George Golumbeski as Class II directors for 3-year terms; Frates received 35.8M for, 11.4M withheld.
Ratified PwC as independent auditor for FY2025 with 50.5M for, 0.7M against.
Advisory say-on-pay approved with 36.0M for, 10.9M against, 3.9M broker non-votes.
Approved amendment to 2014 ESPP increasing authorized shares by 500,000; 41.0M for, 6.3M against.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.